Hormone News and Research

RSS

A hormone is a chemical released by one or more cells that affects cells in other parts of the organism. Only a small amount of hormone is required to alter cell metabolism. It is essentially a chemical messenger that transports a signal from one cell to another.

MIF exhibits potential as viable therapeutic target for Type 2 diabetes

An experimental oral drug has lowered blood sugar levels and inflammation in mice with Type 2 diabetes, suggesting that the medication could someday be added to the arsenal of drugs used by millions of Americans with this disease, according to new research.

16 Mar 2010

Novo Nordisk awarded funds to support diabetes summer camps nationwide

Novo Nordisk Inc., a world leader in diabetes care, announced that it has awarded funds to support scholarships and capital improvements to diabetes summer camps at fifteen locations nationwide. In support of their dedication to meeting the needs of children with diabetes, the grants will help the camps provide financial assistance programs to campers and improve facilities for the campers' use.

From Novo Nordisk 16 Mar 2010

CT scan of heart's epicardial fat provides better prognosis compared to standard diagnostic techniques

Imaging epicardial adipose tissue, or the layer of fat around the heart, can provide extra information compared with standard diagnostic techniques such as coronary artery calcium scoring, according to research by cardiologists at Emory University School of Medicine.

16 Mar 2010

Metabolic drugs top the list of prescription drug expenses for elderly Medicare beneficiaries

Purchases of cholesterol and diabetes prescription drugs by elderly Medicare beneficiaries reached nearly $19 billion in 2007 - about one-fourth of the approximately $82 billion spent for medications for the elderly, according to the latest AHRQ News and Numbers.

16 Mar 2010

Kisspeptin injections may help restore women's fertility

Twice weekly injections of the hormone kisspeptin may provide a new treatment to restore fertility in some women. The research is being presented at the Society for Endocrinology BES meeting in Manchester.

16 Mar 2010

GTx reacquires full rights to Ostarine

GTx, Inc. today provided a company update and reported financial results for the fourth quarter and full year 2009.

15 Mar 2010

NDA for BYDUREON: FDA issues complete response letter

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration has issued a complete response letter regarding the New Drug Application for BYDUREON™ (exenatide for extended-release injectable suspension).

15 Mar 2010

Ipsen commences dosing in two BIM 23A760 phase II studies for neuroendocrine tumors and acromegaly

Ipsen announced today the initiation of dosing in two phase II clinical studies to evaluate efficacy and safety of BIM 23A760 in two groups of patients, one suffering from carcinoid syndrome due to neuroendocrine tumors, the other from acromegaly.

15 Mar 2010

Puzzle baffled scientists for centuries - why some birds appear to be half male and half female solved

A puzzle that has baffled scientists for centuries - why some birds appear to be male on one side of the body and female on the other - has been solved by researchers.

15 Mar 2010

Painful periods at early age doubles risk of endometriosis

Queensland Institute of Medical Research scientists have identified a new link between strong period pain experienced in adolescence and early adulthood and the risk of endometriosis.

15 Mar 2010

Obese type 2 diabetics carry mitochondrial proteins that reduce response to physical exercise

Diet and aerobic exercise are highly effective for the treatment of type 2 diabetes, but not for obese subjects that have developed the disease when very young. A study at the Institute for Research in Biomedicine and Trinity College in Dublin demonstrates that obese subjects between 18 and 25 years of age carry mitochondrial proteins and genes that work abnormally and that these anomalies contribute to generating insulin resistance and a reduced response to physical exercise.

15 Mar 2010

CBio recruits 75th patient into XToll phase II clinical trial, achieves milestone under agreement with Novo Nordisk

Australian drug development company CBio Limited today announced the achievement of a clinical trial milestone under its option agreement with global pharmaceutical leader Novo Nordisk A/S. The agreement relates to the development of XToll, the potential new-generation drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis (RA).

12 Mar 2010

Study shows experimental thyroid drug reduces cholesterol

An experimental thyroid drug reduces cholesterol without the troublesome side effects experienced by some people on statins, according to a study published today in The New England Journal of Medicine. An international team of investigators at Johns Hopkins Medical Institutions, the Karolinska University Hospital and Institute, and The Feinstein Institute for Medical Research tested a substance called Eprotirome in patients with high cholesterol.

12 Mar 2010

New method to better study prostate cancer

Van Andel Research Institute researchers have developed a new method to better study the cells that line and protect the prostate in relation to the development of cancer. Using the model, they found that normal cells and cancer cells depend on different factors to survive, which could aid in discovering how to target cancer cells without affecting normal cells when developing treatments.

12 Mar 2010

Independently-conducted studies confirm significant bioavailability of orally delivered insulin

ACCESS PHARMACEUTICALS, INC. announced that it has received reports of significant bioavailability of orally delivered insulin in two independently-conducted animal studies. The studies, which confirm earlier findings, were performed as part of on-going work with commercial collaborators that are evaluating Access' Cobalamin™ Oral Drug Delivery Technology.

12 Mar 2010

Genentech announces topline results from Phase III trial of Avastin

Genentech, Inc., a wholly owned member of the Roche Group, announced today the topline results of a Phase III trial led by the U.S. Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of Avastin® (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC).

12 Mar 2010

Ipsen grants Rhythm exclusive global license for melanocortin and ghrelin programs

Ipsen, a global biotechnology specialty care group, and Rhythm Pharmaceuticals, a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that they have concluded a license agreement for Ipsen’s proprietary peptide therapeutics targeting obesity, metabolic diseases, and gastrointestinal disorders.

12 Mar 2010

Abbott's sNDA for new six-month 45-mg formulation of Lupron Depot: FDA accepts for review

The U.S. Food and Drug Administration has accepted for review the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron® Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancer. Palliative treatment helps to relieve symptoms associated with advanced prostate cancer.

12 Mar 2010

Study explores incidence of eating disorders among type 1 diabetic patients

Diabetics, under the gun to better manage their disease by controlling their food intake and weight, may find themselves in the sticky wicket of needing treatment that makes them hungry, researchers said.

12 Mar 2010

Watson Pharmaceuticals' TRELSTAR receives FDA approval for treatment of advanced prostate cancer

Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.

11 Mar 2010

Hormone News and Research

Further Reading

MIF exhibits potential as viable therapeutic target for Type 2 diabetes

Novo Nordisk awarded funds to support diabetes summer camps nationwide

CT scan of heart's epicardial fat provides better prognosis compared to standard diagnostic techniques

Metabolic drugs top the list of prescription drug expenses for elderly Medicare beneficiaries

Kisspeptin injections may help restore women's fertility

GTx reacquires full rights to Ostarine

NDA for BYDUREON: FDA issues complete response letter

Ipsen commences dosing in two BIM 23A760 phase II studies for neuroendocrine tumors and acromegaly

Puzzle baffled scientists for centuries - why some birds appear to be half male and half female solved

Painful periods at early age doubles risk of endometriosis

Obese type 2 diabetics carry mitochondrial proteins that reduce response to physical exercise

CBio recruits 75th patient into XToll phase II clinical trial, achieves milestone under agreement with Novo Nordisk

Study shows experimental thyroid drug reduces cholesterol

New method to better study prostate cancer

Independently-conducted studies confirm significant bioavailability of orally delivered insulin

Genentech announces topline results from Phase III trial of Avastin

Ipsen grants Rhythm exclusive global license for melanocortin and ghrelin programs

Abbott's sNDA for new six-month 45-mg formulation of Lupron Depot: FDA accepts for review

Study explores incidence of eating disorders among type 1 diabetic patients

Watson Pharmaceuticals' TRELSTAR receives FDA approval for treatment of advanced prostate cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News